查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1808879

纖維瘤市場，按藥物類型、按配銷通路、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率及預測

Desmoid Tumors Market, By Drug Type, By Distribution channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年，纖維瘤市場規模價值 29.6591 億美元，2025 年至 2032 年的複合年成長率為 9.20%。

纖維瘤是一種罕見的非癌性（良性）腫瘤，由結締組織細胞形成，通常位於包圍肌肉、神經和血管的筋膜中。這類腫瘤具有局部侵襲性，這意味著它們可以生長並侵入附近的結構，但不會像傳統癌症那樣擴散到身體的其他部位。

纖維瘤市場-市場動態

全球癌症發生率上升推動纖維瘤市場成長

預計癌症發生率上升將推動未來纖維瘤市場的成長。癌症是一組以體內異常細胞失控生長和擴散為特徵的疾病。這些細胞會侵入附近的組織和器官，造成傷害。全球癌症病例的增加增加了對有效和先進化療藥物的需求，這對纖維瘤市場產生了積極影響。例如，根據美國聯邦政府機構國家癌症研究所的數據，到 2024 年 5 月，美國預計將診斷出 2,001,140 例新的癌症病例，預計會有 611,720 人死於癌症。 2022 年，全球新增癌症病例近 2,000 萬例，死亡人數達 970 萬人。到 2040 年，預計每年新增癌症病例將達到 2,990 萬例，癌症相關死亡人數將達到 1,530 萬例。因此，癌症發生率的上升正在推動纖維瘤市場的成長。

纖維瘤市場—關鍵洞察

v 根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 9.20%

v 根據藥物類型細分，化療領域將成為 2025 年全球市場中最大的領域

v 根據配銷通路細分，醫院藥房部門預計將佔據全球市場的大部分佔有率。

v 按地區分類，北美是 2024 年的主要收入來源

纖維瘤市場-細分分析：

全球纖維瘤市場根據藥物類型、配銷通路和地區進行細分。

根據藥物類型，市場分為五類：非類固醇抗發炎藥 (NSAID)、化療、標靶治療、荷爾蒙治療和其他。化療領域在 2025 年是全球市場中最大的領域，預計在預測期內將繼續主導市場。化療雖然傳統上與全身性副作用有關，但仍是重要的治療選擇，特別是對於侵襲性或無法手術的腫瘤。根據個別患者需求量身訂做的合併用藥方案提高了療效和耐受性。此外，對具有更好安全性的新型化療藥物的持續研究預計將推動該領域的成長。儘管面臨挑戰，化療仍是治療方法的重要組成部分。

根據配銷通路，市場分為三類：醫院藥房、零售藥房和線上藥房。預計在預測期內，醫院藥局將佔據全球市場的絕大部分。醫院藥局是纖維瘤治療的重要配銷通路，因為它們可以直接接觸在醫療機構接受治療的患者。這些藥房確保了基本藥物的供應，並充當了醫療服務提供者和患者之間的重要紐帶。它們在管理藥物供應和提供諮詢服務方面的作用對整個治療過程至關重要。

纖維瘤市場—地理洞察

北美是全球纖維瘤市場最大的區域，預計在預測期內仍將保持領先地位。醫療保健支出的不斷成長、技術進步的快速應用、認知度的不斷提高以及北美纖維瘤患病率的不斷上升，都推動了該市場的成長。 MRI 和 CT 掃描等影像技術的進步提高了檢測和定位纖維瘤的能力。

預計亞太地區在預測期內的複合年成長率將位居全球市場之首。不斷成長的患者群體、醫療投資和基礎設施建設的增加，以及人們對罕見疾病的認知度和醫療保健可近性的提高，是推動亞太地區纖維瘤市場發展的主要因素。

纖維瘤市場-競爭格局：

纖維瘤市場競爭激烈，製藥公司和研究機構都致力於開發有效的治療方案。主要參與者包括 Horizo​​n Therapeutics Plc、Strides Pharma Science Limited、Teva Pharmaceutical Industries Ltd 和 Amneal Pharmaceuticals LLC，後者參與了標靶療法的臨床試驗。專注於創新研發的小型生物技術公司和學術機構也為市場做出了貢獻。競爭的驅動力在於改善治療效果、減少副作用以及滿足患者未滿足的醫療需求。這既包括標靶藥物和免疫療法等新療法的開發，也包括現有療法的改進。監管部門的批准、臨床試驗結果和專利性都會影響競爭環境。

最新動態：

v 2023年8月，Horizo​​​​n Therapeutics Plc 宣佈在美國推出注射用Krystexxa(R)（聚乙二醇化brentuximab vedotin），用於治療既往接受過含蒽環類藥物化療的不可切除或複發性局部晚期或轉移性軟組織肉瘤（STS）成年患者。

目錄

第 1 章：纖維瘤市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 纖維瘤市場（按藥物類型）
    • 纖維瘤市場（按配銷通路）
    • 各國家/地區纖維瘤市場摘要
    • 纖維瘤市場（按地區）
  • 競爭洞察

第3章：纖維瘤的主要市場趨勢

  • 纖維瘤市場促進因素
    • 市場促進因素的影響分析
  • 纖維瘤市場限制
    • 市場限制的影響分析
  • 纖維瘤市場機遇
  • 纖維瘤市場未來趨勢

第4章：纖維瘤產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：纖維瘤市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：纖維瘤市場格局

  • 2024年纖維瘤市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：纖維瘤市場－依藥物類型

  • 概述
    • 按藥物類型分類的細分市場佔有率分析
    • 非類固醇抗發炎藥（NSAIDs）
    • 化療
    • 標靶治療
    • 荷爾蒙療法
    • 其他

第 8 章：纖維瘤市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第9章：纖維瘤市場－按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美纖維瘤主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（依藥品類型）
    • 北美市場規模及預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲纖維瘤主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（依藥品類型）
    • 歐洲市場規模及預測（按配銷通路）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區纖維瘤主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依藥品類型）
    • 亞太地區市場規模及預測（按配銷通路）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲纖維瘤主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按藥物類型）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的纖維瘤主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依藥物類型）
    • MEA 市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 10 章：關鍵供應商分析-纖維瘤產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Horizon Therapeutics Plc
    • Strides Pharma Science Limited
    • Teva Pharmaceutical Industries Ltd
    • Amneal Pharmaceuticals LLC
    • Hikma Pharmaceuticals PLC
    • Natco Pharma Ltd
    • Lupin, Zydus Lifesciences
    • Mylan NV
    • Assertio Holdings, Inc.
    • Mayne Pharma Group Limited
    • Alembic Pharmaceuticals Limited, Aprazer
    • Ayala Pharmaceuticals
    • SpringWorks Therapeutics, Inc
    • Iterion Therapeutics
    • Novartis AG
    • Apotex Inc.
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd
    • Dr. Reddy's Laboratories Ltd
    • Endo International plc
    • Abbott
    • Getwell Pharmaceuticals
    • Others

第 11 章：360 度分析師視角

第 12 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5512

Desmoid Tumors Market size was valued at US$ 2,965.91 Million in 2024, expanding at a CAGR of 9.20% from 2025 to 2032.

Desmoid tumors are rare non-cancerous (benign) tumors that form from connective tissue cells, typically in the fascia, which surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means that they can grow and invade nearby structures but do not spread to other parts of the body like traditional cancer.

Desmoid Tumors Market- Market Dynamics

O Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market

Rising cancer rates are expected to drive future growth in the desmoid tumor market. Cancer is a group of disorders characterized by the body's abnormal cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs, causing damage. The rising number of cancer cases worldwide has increased the demand for effective and advanced chemotherapeutic agents, which has a positive impact on the desmoid tumor market. For instance, in May 2024, according to the National Cancer Institute, a federal government agency based in the United States In 2024, an estimated 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected due to the disease. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide. By 2040, the annual number of new cancer cases is expected to reach 29.9 million, with 15.3 million cancer-related deaths. As a result, rising cancer rates are driving the growth of the desmoid tumor market.

Desmoid Tumors Market- Key Insights

v As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.20% over the forecast period (2025-2032)

v Based on Drug Type segmentation, the chemotherapy segment is the largest in the global market in 2025

v Based on Distribution channel segmentation, the hospital pharmacies segment is anticipated to hold the majority of the global market.

v On the basis of region, North America was the leading revenue generator in 2024

Desmoid Tumors Market- Segmentation Analysis:

The Global Desmoid Tumors Market is segmented on the basis of Drug Type, Distribution channel, and Region.

The market is divided into five categories based on Drug Type: Non-steroidal anti-inflammatory drugs (NSAIDs), Chemotherapy, Targeted Therapy, Hormone Therapy and Others. The chemotherapy segment is the largest in the global market in 2025, and it is expected to continue to dominate the market during the forecast period. Chemotherapy, while traditionally associated with systemic side effects, remains an important treatment option, particularly for aggressive or inoperable tumors. Combination drug regimens tailored to individual patient needs have increased efficacy and tolerability. Furthermore, ongoing research into new chemotherapeutic agents with better safety profiles is expected to fuel growth in this segment. Despite its challenges, chemotherapy is still an important part of the treatment arsenal.

The market is divided into three categories based on Distribution channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment is expected to account for the majority of the global market during the forecast period. Hospital pharmacies are an important distribution channel for desmoid tumor treatments because they have direct access to patients receiving treatment in healthcare facilities. These pharmacies ensure the availability of essential medications and serve as a vital link between healthcare providers and patients. Their role in managing medication supply and offering counseling services is critical to the overall treatment process.

Desmoid Tumors Market- Geographical Insights

North America is the largest regional segment in the global desmoid tumors market, and it is expected to maintain its lead position during the forecast period. Rising healthcare expenditure, rapid adoption of technological advancements, growing awareness, and rising prevalence of desmoid tumors in North America all contribute to the market's growth. Imaging advancements, such as MRI and CT scans, have improved the ability to detect and locate desmoid tumors.

The Asia-Pacific region is expected to have the highest CAGR in the global market over the forecast period. The growing patient population, increased healthcare investments and infrastructure development, and increased awareness of rare diseases and access to healthcare are the primary drivers of the desmoid tumors market in Asia-Pacific.

Desmoid Tumors Market- Competitive Landscape:

The desmoid tumors market is competitive, with pharmaceutical companies and research institutions all working to develop effective treatment options. Key players include Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, and Amneal Pharmaceuticals LLC, which has participated in clinical trials for targeted therapies. Smaller biotech firms and academic institutions focused on innovative research and development contribute to the market as well. Competition is driven by the need to improve treatment outcomes, reduce side effects, and meet patients' unmet medical needs. This includes both the development of new therapies, such as targeted drugs and immunotherapies, and the enhancement of existing treatments. Regulatory approvals, clinical trial results, and patentability all have an impact on the competitive environment.

Recent Developments:

v In August, 2023, Horizon Therapeutics Plc has announced the launch of Krystexxa(R) (PEGylated brentuximab vedotin) for injection in the United States for the treatment of adult patients with unresectable or recurrent locally advanced or metastatic soft tissue sarcoma (STS) who have previously received anthracycline-containing chemotherapy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DESMOID TUMORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • O Horizon Therapeutics Plc
  • O Strides Pharma Science Limited
  • O Teva Pharmaceutical Industries Ltd
  • O Amneal Pharmaceuticals LLC
  • O Hikma Pharmaceuticals PLC
  • O Natco Pharma Ltd
  • O Lupin, Zydus Lifesciences
  • O Mylan N.V.
  • O Assertio Holdings, Inc.
  • O Mayne Pharma Group Limited
  • O Alembic Pharmaceuticals Limited, Aprazer
  • O Ayala Pharmaceuticals
  • O SpringWorks Therapeutics, Inc
  • O Iterion Therapeutics
  • O Novartis AG
  • O Apotex Inc.
  • O Bayer AG
  • O Sun Pharmaceutical Industries Ltd
  • O Dr. Reddy's Laboratories Ltd
  • O Endo International plc
  • O Abbott
  • O Getwell Pharmaceuticals
  • O Others

GLOBAL DESMOID TUMORS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • O Non-steroidal anti-inflammatory drugs(NSAIDs)
  • O Chemotherapy
  • O Targeted Therapy
  • O Hormone Therapy
  • O Others

GLOBAL DESMOID TUMORS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • O Hospital Pharmacies
  • O Retail Pharmacies
  • O Online Pharmacies

GLOBAL DESMOID TUMORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • O North America
  • U.S.
  • Canada
  • O Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • O Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • O Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • O The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Desmoid Tumors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Desmoid Tumors Market Snippet by Drug Type
    • 2.1.2. Desmoid Tumors Market Snippet by Distribution channel
    • 2.1.3. Desmoid Tumors Market Snippet by Country
    • 2.1.4. Desmoid Tumors Market Snippet by Region
  • 2.2. Competitive Insights

3. Desmoid Tumors Key Market Trends

  • 3.1. Desmoid Tumors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Desmoid Tumors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Desmoid Tumors Market Opportunities
  • 3.4. Desmoid Tumors Market Future Trends

4. Desmoid Tumors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Desmoid Tumors Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Desmoid Tumors Market Landscape

  • 6.1. Desmoid Tumors Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Desmoid Tumors Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Non-steroidal anti-inflammatory drugs(NSAIDs)
    • 7.1.3. Chemotherapy
    • 7.1.4. Targeted Therapy
    • 7.1.5. Hormone Therapy
    • 7.1.6. Others

8. Desmoid Tumors Market - By Distribution channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution channel, 2024 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Desmoid Tumors Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Desmoid Tumors Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Desmoid Tumors Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.7. UK
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. UK Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.8. France
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.9. Italy
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.10. Spain
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Spain Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.11. The Netherlands
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. The Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.13. Russia
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.14. Poland
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.3.15. Rest of Europe
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Desmoid Tumors Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.6. China
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.6.4. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.11. Indonesia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.12. Thailand
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Desmoid Tumors Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Desmoid Tumors Key Manufacturers in Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.7. UAE
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. UAE Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Desmoid Tumors Industry

  • 10.1. Competitive Benchmarking
    • 10.1.1. Competitive Dashboard
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Horizon Therapeutics Plc
    • 10.2.2. Strides Pharma Science Limited
    • 10.2.3. Teva Pharmaceutical Industries Ltd
    • 10.2.4. Amneal Pharmaceuticals LLC
    • 10.2.5. Hikma Pharmaceuticals PLC
    • 10.2.6. Natco Pharma Ltd
    • 10.2.7. Lupin, Zydus Lifesciences
    • 10.2.8. Mylan N.V.
    • 10.2.9. Assertio Holdings, Inc.
    • 10.2.10. Mayne Pharma Group Limited
    • 10.2.11. Alembic Pharmaceuticals Limited, Aprazer
    • 10.2.12. Ayala Pharmaceuticals
    • 10.2.13. SpringWorks Therapeutics, Inc
    • 10.2.14. Iterion Therapeutics
    • 10.2.15. Novartis AG
    • 10.2.16. Apotex Inc.
    • 10.2.17. Bayer AG
    • 10.2.18. Sun Pharmaceutical Industries Ltd
    • 10.2.19. Dr. Reddy's Laboratories Ltd
    • 10.2.20. Endo International plc
    • 10.2.21. Abbott
    • 10.2.22. Getwell Pharmaceuticals
    • 10.2.23. Others

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us